Nuzenio

Marketbeat Inhibikase Therapeutics

Marketbeat Inhibikase Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 5 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Sun, 09 Aug 2026 06:21:56 GMTInhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Sun, 02 Aug 2026 07:00:00 GMTPerceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Wed, 29 Jul 2026 07:00:00 GMTAlly Bridge Group NY LLC Makes New Investment in Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Wed, 29 Jul 2026 07:00:00 GMTSummitTX Capital L.P. Acquires New Position in Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Wed, 29 Jul 2026 07:00:00 GMTADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT - MarketBeat

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Marketbeat Inhibikase Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

1 distinct publisher/source names are currently connected to this entity page.